Can you take IDA with Tetrabenazine?

The acetaminophen in IDA has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

Tetrabenazine has a major potential interaction with Arrhythmia.

Tetrabenazine can cause an increase in the corrected QT interval. QT prolongation can lead to the development of ventricular arrhythmias. The use of tetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of arrhythmias.

Tetrabenazine has a moderate potential interaction with Breast Cancer.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

The acetaminophen in IDA has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The dichloralphenazone in IDA has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Tetrabenazine has a major potential interaction with Depression.

The use of tetrabenazine is contraindicated in patients with untreated or uncontrolled depression. Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior.

Tetrabenazine has a moderate potential interaction with Dysphagia.

Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia. Caution should be exercised when used in patients with conditions that predispose to dysphagia. Special caution is advised in patients with Huntington's disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.

The isometheptene mucate in IDA has a major potential interaction with Glaucoma/Intraocular Hypertension.

The use of combination drugs that have isometheptene mucate may be contraindicated in patients with glaucoma and/or severe cases of renal disease, hypertension, organic heart disease, or hepatic disease.

The dichloralphenazone in IDA has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The isometheptene mucate in IDA has a major potential interaction with High Blood Pressure.

The use of combination drugs that have isometheptene mucate may be contraindicated in patients with glaucoma and/or severe cases of renal disease, hypertension, organic heart disease, or hepatic disease.

Tetrabenazine has a major potential interaction with Huntington's Disease.

Patients with Huntington disease are prone to depression. Tetrabenazine can increase the risk of depression and suicidal thoughts and should be used with caution in patients with Huntington's disease. The benefits and risks of treatment should be considered before starting therapy, and patients should be under close observation for emergence or worsening of depression symptoms. The family and caregivers should also be informed of this risk and should be instructed to report any changes in behavior or any concerns to the treating physician.

Tetrabenazine has a moderate potential interaction with Huntington's Disease.

Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia. Caution should be exercised when used in patients with conditions that predispose to dysphagia. Special caution is advised in patients with Huntington's disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.

Tetrabenazine has a moderate potential interaction with Hyperprolactinemia.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

Tetrabenazine has a moderate potential interaction with Hypotension.

Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.

The acetaminophen in IDA has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The isometheptene mucate in IDA has a major potential interaction with Liver Disease.

The use of combination drugs that have isometheptene mucate may be contraindicated in patients with glaucoma and/or severe cases of renal disease, hypertension, organic heart disease, or hepatic disease.

Tetrabenazine has a major potential interaction with Liver Disease.

The use of tetrabenazine is contraindicated in patients with hepatic impairment. The safety and efficacy of exposure to the drug and other metabolites are unknown and it is not possible to adjust the dosage in hepatic impairment to ensure safe use.

The dichloralphenazone in IDA has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

The acetaminophen in IDA has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Tetrabenazine has a moderate potential interaction with Osteoporosis.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

The acetaminophen in IDA has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

The isometheptene mucate in IDA has a major potential interaction with Renal Dysfunction.

The use of combination drugs that have isometheptene mucate may be contraindicated in patients with glaucoma and/or severe cases of renal disease, hypertension, organic heart disease, or hepatic disease.

Tetrabenazine has a moderate potential interaction with Syncope.

Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.

The dichloralphenazone in IDA has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.